Mizuho restated their buy rating on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a report released on Tuesday morning. They currently have a $53.00 target price on the stock, down from their prior target price of $54.00.

A number of other research firms have also recently issued reports on PCRX. Royal Bank Of Canada set a $58.00 price target on shares of Pacira Pharmaceuticals and gave the stock a buy rating in a report on Monday, May 15th. Canaccord Genuity reaffirmed a buy rating and issued a $60.00 price target on shares of Pacira Pharmaceuticals in a report on Monday, May 15th. Cowen and Company reaffirmed a hold rating on shares of Pacira Pharmaceuticals in a report on Friday, July 14th. Wedbush reaffirmed an outperform rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, July 19th. Finally, Zacks Investment Research cut shares of Pacira Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, May 2nd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. The stock has an average rating of Hold and an average price target of $53.92.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 35.85 on Tuesday. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95. The company’s market capitalization is $1.45 billion. The firm’s 50-day moving average price is $42.75 and its 200-day moving average price is $45.28.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.06. The company had revenue of $70.90 million during the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.21 EPS. Analysts anticipate that Pacira Pharmaceuticals will post ($0.12) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/23/pacira-pharmaceuticals-pcrx-buy-rating-reaffirmed-at-mizuho.html.

In other news, SVP Scott Braunstein sold 768 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $33,269.76. Following the sale, the senior vice president now owns 9,982 shares in the company, valued at $432,420.24. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO David M. Stack sold 4,311 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $43.32, for a total transaction of $186,752.52. Following the completion of the sale, the chief executive officer now owns 59,559 shares in the company, valued at approximately $2,580,095.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,869 shares of company stock worth $1,590,276. Company insiders own 6.60% of the company’s stock.

Several hedge funds have recently made changes to their positions in PCRX. Renaissance Technologies LLC raised its stake in shares of Pacira Pharmaceuticals by 1.6% in the fourth quarter. Renaissance Technologies LLC now owns 25,200 shares of the company’s stock valued at $814,000 after buying an additional 400 shares during the period. Teachers Advisors LLC increased its position in Pacira Pharmaceuticals by 6.2% in the fourth quarter. Teachers Advisors LLC now owns 62,854 shares of the company’s stock valued at $2,030,000 after buying an additional 3,658 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new position in Pacira Pharmaceuticals during the first quarter valued at $2,736,000. Nationwide Fund Advisors increased its position in Pacira Pharmaceuticals by 147.4% in the first quarter. Nationwide Fund Advisors now owns 56,190 shares of the company’s stock valued at $2,562,000 after buying an additional 33,482 shares in the last quarter. Finally, Fisher Asset Management LLC acquired a new position in Pacira Pharmaceuticals during the first quarter valued at $285,000.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.